Methotrexate

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

ATC codes: L01BA01

Indication	Malignant trophoblastic neoplasms of placenta ICD11 code: 2C75.0
INN	Methotrexate
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 50 mg in vial (as sodium salt) ; 50 mg per 2 mL ; 1000 mg per 10 mL concentrated injection **Oral > Solid:** 2.5 mg (as sodium salt)
EML status history	First added in 2015 (TRS 994) Changed in 2023 (TRS 1049)
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Methotrexate
DrugBank	Methotrexate

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional dose forms of methotrexate (Injection: 50 mg/2 mL and Concentrated injection: 1000 mg/10 mL) to the EML and EMLc.